Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5502 in Healthy Adults and Participants With Primary Sjögren's Syndrome
NCT06544642Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP5502 in Sjögren's syndrome (4 arms), sponsored by Astellas Pharma. Primary endpoints: Number of Participants With Adverse Events, Number of participants with laboratory value abnormalities and/or AEs and 2 more. Started Aug 2024; status: terminated.
02
Drugs
ASP5502
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT06544642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544642.